5-{[4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxymethyl}tetrazole | 90444-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-{[4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxymethyl}tetrazole
• 英文别名: 5-({[4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridin-2-yl]methoxy}methyl)tetrazole；5-{[4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxymethyl]tetrazole；5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2-methyl-6-(2H-tetrazol-5-ylmethoxymethyl)-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 90444-78-3
• 化学式: C₂₀H₂₁Cl₂N₅O₅
• 分子量: 482.323
• InChiKey: FSGYJFOCGMPJBZ-UHFFFAOYSA-N

物化性质

• 熔点：
  112-114 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  623.1±65.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-{[4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxymethyl}tetrazole 、 碘甲烷 、 氢氧化钾 以23%的产率得到
  参考文献：
  名称：

  ALKER, DAVID;CAMPBELL, SIMON F.;CROSS, PETER E.;BURGES, ROGER A.;CARTER, +, J. MED. CHEM., 32,(1989) N0, C. 2381-2388

  摘要：

  DOI：
• 作为产物：
  描述：

  2-<<4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridin-2-yl>methoxy>acetic acid 在 吡啶 、 盐酸 、 氨 、 N,N'-羰基二咪唑 、 三正丁基叠氮化锡 、 三氟乙酸酐 作用下， 以 1,4-二氧六环 为溶剂， 反应 40.83h， 生成 5-{[4-(2,3-Dichlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxymethyl}tetrazole
  参考文献：
  名称：

  Long-acting dihydropyridine calcium antagonists. 3. Synthesis and structure-activity relationships for a series of 2-[(heterocyclylmethoxy)methyl] derivatives

  摘要：

  The preparation of 1,4-dihydropyridines containing (heterocyclylmethoxy)methyl groups in the 2-position is described and the structural identification of certain of the compounds using 1H NMR spectroscopic methods is reported. The calcium antagonist activity of the compounds on rat aorta is listed and is compared with the negative inotropic potency as determined by using a Langendorff-perfused guinea pig heart model. Several compounds are more potent than nifedipine and show greater selectivity for the vasculature over the heart. One compound, 2-[(2-amino-4-hydroxypyrimidin-6-yl)methoxy]-4- (2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl- 1,4-dihydropyridine (27, UK-56,593), was identified as a potent (IC50 = 1.6 x 10(-9) M), tissue-selective calcium antagonist which proved to have a markedly longer duration of action (greater than 4.5 h) than nifedipine in the anesthetized dog on intravenous administration.

  DOI：

  10.1021/jm00130a026

文献信息

• Dihydropyridine anti-ischaemic and antihypertensive agents
  申请人：Pfizer Inc.

  公开号：US04515799A1

  公开（公告）日：1985-05-07

  1,4-Dihydropyridine derivatives of the formula: ##STR1## wherein R is aryl or heteroaryl; R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl; Y is --(CH.sub.2).sub.n --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 13 ; n is 1 to 3; and X is a 5 or 6 membered nitrogen containing aromatic heterocyclic ring which may optionally be substituted by one or more C.sub.1 -C.sub.4 alkyl, phenyl, benzyl, CN, --N(R.sup.3).sub.2, (CH.sub.2).sub.m CO.sub.2 H, (CH.sub.2).sub.m CO.sub.2 (C.sub.1 -C.sub.4 alkyl) or (CH.sub.2).sub.m CON(R.sup.3).sub.2 group wherein each R.sup.3 is independently H or C.sub.1 -C.sub.4 alkyl and m is 0 or 1; and their pharmaceutically acceptable acid addition salts, and pharmaceutical preparation containing such compounds, have utility as anti-ischaemic and antihypertensive agents.

  1,4-二氢吡啶衍生物的化学式为：其中R为芳基或杂环芳基；R.sup.1和R.sup.2分别独立为C.sub.1-C.sub.4烷基或2-甲氧基乙基；Y为--(CH.sub.2).sub.n --，--CH.sub.2 CH(CH.sub.3)--或--CH.sub.2 C(CH.sub.3).sub.2 ；n为1至3；X为含有5或6个成员的氮含杂环芳香环，可能可选地被一个或多个C.sub.1-C.sub.4烷基，苯基，苄基，CN，--N(R.sup.3).sub.2，(CH.sub.2).sub.m CO.sub.2 H，(CH.sub.2).sub.m CO.sub.2 (C.sub.1-C.sub.4烷基)或(CH.sub.2).sub.m CON(R.sup.3).sub.2基团取代；其中每个R.sup.3独立地为H或C.sub.1-C.sub.4烷基，m为0或1；以及它们的药学上可接受的酸盐，以及含有这些化合物的药物制剂，具有作为抗缺血和降压药物的用途。
• US4515799A
  申请人：——

  公开号：US4515799A

  公开（公告）日：1985-05-07
• US4548935A
  申请人：——

  公开号：US4548935A

  公开（公告）日：1985-10-22
• US4616024A
  申请人：——

  公开号：US4616024A

  公开（公告）日：1986-10-07